Lumito presents results from the successful proof of concept phase
As previously disclosed the results from the first histological assay (Link to supporting material) are very promising and corroborate a rapid development and release of Lumito’s unique products to the market. Lumito performed the assay together with the company’s development partner The Technology Partnership (TTP) and the external research laboratory BioIVT using proof of concept prototypes; tissue staining kit and instrument for digital pathology.
The assay uses sectioned and stained human colon tissue and targets cytokeratin as a marker for epithelial cells. The assay shows that:
1. Lumito’s staining kit can be used with standard autostainers.
2. Lumito’s luminescence imaging and standard brightfield imaging can be multiplexed in one single tissue slide.
3. Lumito’s luminescence imaging can provide high fidelity information about cell subtypes in human tissue.
“The results from the assay are very promising and corroborate what we have expected; a rapid development and release of Lumito’s staining kit and instrument for digital pathology to the market. This indicates that our products should significantly improve the diagnostics for tissue samples with higher quality analysis”, says Stefan Nilsson, CEO of Lumito.
The company is already continuing the work in development step 2 together with TTP aiming for developed alpha and beta versions of both instrument and staining kit.
For more information including images from proof of concept, please refer to https://www.lumito.se/en/technology/concept-phase/
For more information contact:
Lumito AB (publ), CEO Stefan Nilsson, telefon +46 767 78 59 05, email@example.com
Lumito is specialised in research and development of imaging technologies for medical applications. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications.
Lumito´s IPR covers, with UCNP:s as markers, imaging with high quality of for instance tissue samples. The technology has several possible application areas and Lumito has firstly focused on digital pathology.
Lumito has an agreement regarding development of instrument and staining kits with TTP plc (The Technology Partnership) in Cambridge UK.
Lumito shares LUMITO MTF and warrants LUMITO MTF TO1 are traded at the marketplace NGM Nordic MTF.
TTP is an independent technology company where scientists and engineers collaborate to invent, design and develop new products and technologies. With a 30-year history of invention, our multidisciplinary teams are able to deliver across the scope of a project, from research through to ideas, design, engineering and manufacture.
TTP’s state-of-the-art technical facilities are part of Europe's largest technology hub in Cambridge, UK. Here, we work across a wide spectrum of industries - including health, telecoms, industrials and consumer - to create breakthrough solutions that bring strong commercial value to clients and the benefits of technology to all.
BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. It specializes in control and disease-state biospecimens, cell products, blood and other biofluids. It is also the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions. Its PHASEZERO® Research Services team provides target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. www.bioivt.com.